KRAS and colorectal carcinoma: To examine the effect of antibodies on the capacity of CRC to metastasize to the liver, we investigated EGFP-expressing CRC cell lines with the KRAS p.G13D mutation (DLD-1, HCT-15, HCT-116) using a CRC liver metastasis mouse model created by intrasplenic injection [24,25].